The Invesco Dorsey Wright Healthcare Momentum ETF (PTH) receives a Hold rating due to its biotechnology-heavy portfolio showing mixed results. While it has strong quantitative and Wall Street ratings that might help it outperform broader healthcare ETFs like IVV by 2027, its historical performance since 2014 has been underwhelming, especially on risk-adjusted returns and drawdowns. Concerns include a large exposure to companies with negative EBITDA and cash flow, raising questions about portfolio quality. Investors are advised to approach PTH with caution given these underlying risks despite some recent decent performance.
The Invesco Dorsey Wright Healthcare Momentum ETF (PTH) is the subject, with Pluang's Health-sector market data as context. For readers following healthcare stocks, here is Pluang's market snapshot as of Nov 15, 2026 00:41 WIB: out of 150 priced US health-sector stocks, 71 rose and 77 fell. Notable movers include Summit Therapeutics Inc (SMMT) at USD 14.15 with a 1-day change of -6.14%, Ginkgo Bioworks Holdings Inc (DNA) at USD 9.61 down 6.06%, and Aveanna Healthcare Holdings Inc (AVAH) at USD 11.50 down 6.05%.
Celsius Holdings (CELH) has demonstrated a sequential recovery in its Q3 2026 performance, driven by aggressive shelving resets, a Direct Store Delivery strategy, and strong growth from its Alani Nu brand. The company maintained a solid Energy MULO+W...
Stablecoin inflows to Arbitrum, an Ethereum layer-2 network, have increased significantly, with the network's stablecoin market capitalization rising by $43.6 million in a 24-hour period. Stablecoins are crucial in decentralized finance (DeFi) for tr...
Two major Nvidia shareholders, Altimeter Capital and Atreides Management, have called on Nvidia's board to conduct a slow and deliberate CEO search that includes the possibility of Jensen Huang returning. Huang resigned as CEO amid an investigation i...
Savara (SVRA) is rated a speculative BUY at $4.72 with a $7 twelve-month price target, anticipating a crucial FDA decision on November 22 regarding its drug molgramostim. The company shows strong clinical efficacy data in Phase 3 trials, but faces si...
XRP dropped to $0.96, falling out of the top 5 cryptocurrencies by market value, now ranking sixth behind USDC. The coin has lost 26% since November 5, driven by a broader crypto market sell-off and no new inflows into US XRP ETFs since late October....
